Merck & Co snaps up respiratory drug maker Verona for USD10 billion
10th Jul 2025 09:06
(Alliance News) - Merck & Co Inc on Wednesday said it has struck a deal to acquire Verona Pharma PLC, bolstering its respiratory diseases offering. Read More
(Alliance News) - Merck & Co Inc on Wednesday said it has struck a deal to acquire Verona Pharma PLC, bolstering its respiratory diseases offering. Read More
(Alliance News) - Water utility Severn Trent and housebuilder Vistry backed guidance, while advertising firm WPP named a new chief executive. Read More
(Alliance News) - RTW Biotech Opportunities Ltd on Tuesday highlighted clinical developments from Corxel Pharmaceuticals (Shanghai) Co Ltd, its second-largest portfolio holding, including the start of a US phase 2 trial and positive results from a China study of Corxel's lead obesity treatment, CX11. Read More
(Alliance News) - RTW Biotech Opportunities Ltd on Friday provided updates on three of its key listed holdings, highlighting both promising clinical trial results and a significant setback involving one of its biotech investments. Read More
(Alliance News) - RTW Biotech Opportunities Ltd on Monday noted investee Rocket Pharmaceuticals has reported "encouraging" data from a phase 1 clinical trial of its treatment for arrhythmogenic cardiomyopathy. Read More
(Alliance News) - RTW Biotech Opportunities Ltd on Friday noted positive trial data from investee Artios Pharma, for the ongoing study of its lead candidate ART0380. Read More
(Alliance News) - RTW Biotech Opportunities Ltd on Thursday announced a new investment into biotech company Airna, closing its oversubscribed USD155 million series B financing round. Read More
(Alliance News) - RTW Biotech Opportunities Ltd on Monday said it underperformed its benchmarks during 2024, while total net asset value climbed following the takeover of Arix Bioscience PLC. Read More
(Alliance News) - RTW Biotech Opportunities Ltd on Monday said portfolio company Kailera Therapeutics has received positive results from a recent weight loss treatment trial. Read More
(Alliance News) - RTW Biotech Opportunities Ltd on Friday said it has made two separate investments as part of series A and C funding rounds in two clinical-stage firms. Read More
RTW Biotech Opportunities Ltd - investment fund managed by RTW Investments LP that specialises in the life sciences sector - Makes additional investment in Series C extension of Numab Therapeutics, a Swiss clinical stage biotech company focused on the development of multi-specific antibodies in immunology and oncology. Numab's CHF50 million, or USD54.5 million, extension, brought its total Series C funding to CHF180 million. Funds will be used to support its clinical development efforts. RTW Biotech first invested in Numab in May 2021. Read More
(Alliance News) - RTW Biotech Opportunities Ltd said on Friday said it is participating in a EUR65 million Series A financing round for Alesta Therapeutics BV, a Leiden, Netherlands-based biotechnology company focused on developing novel oral therapies for rare diseases with unmet medical needs. Read More
(Alliance News) - RTW Biotech Opportunities Ltd on Monday reported two key developments at its Shanghai-based portfolio company Corxel Pharmaceuticals Co Ltd. Read More
RTW Biotech Opportunities Ltd - investment fund managed by RTW Investments LP that specialises in the life sciences sector - Notes Shanghai-based portfolio company Corxel Pharmaceuticals Co Ltd, formerly Ji Xing Pharmaceuticals Ltd, has had its new drug application for Aficamten accepted by China's National Medical Products Administration. Aficamten is a drug treatment for obstructive hypertrophic cardiomyopathy, a genetic heart condition diagnosed in around 130,000 to 330,000 patients in China, in which the heart muscle becomes abnormally thick and limits the heart's pumping function. The drug has also received breakthrough therapy designation from the US Food & Drug Administration. Corxel was founded and launched by RTW Investments in 2019. Read More
RTW Biotech Opportunities Ltd - investment fund managed by RTW Investments LP that specialises in the life sciences sector - Makes an investment in new portfolio company Evommune Inc, a biotechnology company developing therapies for chronic inflammatory disease, as part of a Series C funding round. The company received a legacy position in Evommune earlier this year after its acquisition of Arix Bioscience and its assets. Read More
(Alliance News) - RTW Biotech Opportunities Ltd on Thursday announced the launch of Kailera Therapeutics, a new investee company, with a series A financing round. Read More
RTW Biotech Opportunities Ltd - investment fund managed by RTW Investments LP that specialises in life sciences sector - Invests in Boston, Massachusetts-based Aktis Oncology Inc, a clinical-stage developer of novel targeted alpha radiopharmaceuticals to treat a range of solid tumours. Alongside other investment vehicles owned by RTW Investments, RTW Biotech co-led Aktis's series B funding round, raising USD175 million. Read More
(Alliance News) - RTW Biotech Opportunities Ltd on Friday noted that portfolio firm BioAge Labs Inc has completed a USD198 million initial public offering. Read More